Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06224218
Other study ID # Study 2023-1335
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date January 15, 2024
Est. completion date August 15, 2027

Study information

Verified date January 2024
Source University of Illinois at Chicago
Contact Ruben Sauer, MD
Phone 3124135288
Email rsauer1@uic.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Surgical treatments for benign prostatic hyperplasia (BPH) are necessary when non-procedural approaches fail to alleviate lower urinary tract symptoms (LUTS) or bladder outlet obstruction (BOO). Open simple prostatectomy and laser enucleation are recommended for prostatic adenoma size greater than 80 ml. Minimally invasive approaches, such as robotic-assisted simple prostatectomy, have gained popularity due to their comparable outcomes with lower morbidity. The introduction of the da Vinci single-port (SP) robotic platform offers potential advantages, but its outcomes have not been thoroughly investigated. This randomized controlled trial aims to compare the outcomes of SP simple prostatectomy performed using the da Vinci robotic platform versus thulium laser enucleation of the prostate for the treatment of BPH and BOO.


Description:

Patients diagnosed with symptomatic BPH and eligible for surgical intervention will be randomized to undergo either SP robotic simple prostatectomy or thulium laser enucleation of the prostate. Primary outcomes will include perioperative parameters (operative time, estimated blood loss, hospital stay), postoperative complications, and functional outcomes (urinary symptoms, urinary flow rate). Secondary outcomes will evaluate perioperative and postoperative complications, oncologic outcomes, and patient-reported quality of life measures. In a recent retrospective study at UI Health from 2017 to 2021, investigators compared 103 procedures, SP robotic prostatectomy versus laser enucleation, 34 SP robotic prostatectomy and 69 laser enucleations. There was no difference in any complication at 30-day post-surgery (21.2% vs. 21.7%, p=0.9517). Investigators recognize SP robotic surgery leads to longer operating times, due to docking the instrument and closing the incision, as well as longer catheter times to allow the cystostomy to heal. While the laser enucleation may be considered less invasive, as no incision is required, the instrumentation of the urethra could lead to urethral strictures. This study aims to provide valuable insights into the clinical outcomes of single port simple prostatectomy using SP robotic platform, compared to laser enucleation of the prostate prospectively. The results of this trial will help guide clinicians and patients in selecting the most appropriate surgical intervention for symptomatic BPH, considering both functional outcomes and morbidity. Both procedures are currently performed at UI Health, they are FDA approved, therefore this is not a safety study. Subject insurance will not impact which subject will receive one procedure or the other, as both procedures are recommended on the American Urological Association guidelines for Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia. The study will be a randomized controlled trial comparing SP simple prostatectomy vs laser enucleation of the prostate. The study findings will improve clinical decision-making and aid in optimizing patient outcomes in the management of BPH.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 116
Est. completion date August 15, 2027
Est. primary completion date January 15, 2027
Accepts healthy volunteers No
Gender Male
Age group 18 Years to 88 Years
Eligibility Inclusion Criteria: - Patients diagnosed with symptomatic Benign Prostatic Hyperplasia (BPH) who fail conservative treatment with drug therapy are eligible for surgical intervention. Exclusion Criteria: - Adults unable to consent Prisoners Cognitive impaired adults Coagulopathy

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Single Port Robotic Surgery
Single port Robotic surgery will remove the whole prostate
Laser Surgery
Laser enucleation will remove chips of the prostate but keeping intact the prostate capsule.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
University of Illinois at Chicago

References & Publications (2)

Bove AM, Brassetti A, Ochoa M, Anceschi U, D'Annunzio S, Ferriero M, Tuderti G, Misuraca L, Mastroianni R, Cartolano S, Torregiani G, Lombardo R, De Nunzio C, Simone G. Robotic simple prostatectomy vs HOLEP, a 'multi single-center' experiences comparison. — View Citation

Talamini S, Lai A, Palmer C, van de Walle G, Zuberek M, Crivellaro S. Surgical treatment of benign prostatic hyperplasia: Thulium enucleation versus single-port transvesical robotic simple prostatectomy. BJUI Compass. 2023 Jun 22;4(5):549-555. doi: 10.100 — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Operative time Time in minutes from the start to finish of the procedure. During procedure
Primary International Consultation of Incontinence Questionnaire Short Form How often do you leak urine? never 0 about once a week 1 two or three times a week 2 about once a day 3 several times a day 4 all the time 5
How much urine do you usually leak (whether you wear protection or not)? none 0 a small amount 2 a moderate amount 4 a large amount 6
Overall, how much does leaking urine interfere with your everyday life? 0 (not at all) and 10 (a great deal) 0 1 2 3 4 5 6 7 8 9 10
ICIQ score: sum previous questions.
When does urine leak? never - urine does not leak before you can get to the toilet when you cough or sneeze when you are asleep when you are physically active/exercising when you have finished urinating and are dressed for no obvious reason all the time
Before procedure and 7 months after procedure
Primary Sexual Health Inventory for Men (SHIM) How do you rate your confidence to keep an erection? 1 Very low 2 3 4 5 Very high
How often were your erections hard enough for penetration? 1 Almost never 2 3 4 5Almost always
How often were you able to maintain your erection after you had penetrated your partner? 1Almost never 2 3 4 5Almost always
How difficult was it to maintain your erection to completion of intercourse? 1Extremely difficult 2 3 4 5Not difficult
When you attempted sexual intercourse, how often was it satisfactory for you? 1Almost never 2 3 4 5Almost always
Add together the numbers. If the patient's score is 21 or less, erectile dysfunction (ED) should be addressed.
22 - 25: No significant erectile dysfunction 17 - 21: Mild erectile dysfunction 12 - 16: Mild-to-moderate erectile dysfunction 8 - 11: Moderate erectile dysfunction 5 - 7: Severe erectile dysfunction
Before procedure and 7 months after procedure
Primary International Prostate Symptom Score I-PSS 1. How often have you had a sensation of not emptying your bladder completely after you finish urinating?
0= not all
less than 1 time in 5
less than half the time
about half the time
more than half the time
almost always
2. How often have you had to urinate again less than two hours after you have finished urinating?
0 1 2 3 4 5
3. How often have you found you stopped and started again several times when you urinated?
0 1 2 3 4 5
4. How often have you found it difficult to postpone urination?
0 1 2 3 4 5
5. How often have you had a weak urinary stream?
0 1 2 3 4 5
6. How often have you had to push or strain to begin urination?
0 1 2 3 4 5
7. How many times did you most typically get up each night to urinate from the time you went to bed until the time you got up in the morning?
0 1 2 3 4 5
Sum previous questions to have the score:
0 - 7 = mildly symptomatic; 8 - 19 = moderately 20 - 35 = severely
Before procedure and 7 months after procedure
Primary Urinary flow rate Measure of the urine flow in mL/s Before procedure and 7 months after procedure
Primary Post void residual volume Amount of urine retained in the bladder after a voluntary void measure with Ultrasound.
Volume = length x width x height x 0.52
Before procedure and 7 months after procedure
Primary Blood loss during procedure Estimate blood loss in mL during procedure During procedure
Primary Hospital stay after procedure Amount of time spent at the hospital after procedure measure in hours From end of procedure to discharge home (up to 30 days )
Secondary Number of subjects with injuries related to surgical procedures. Descriptive report of complications during surgery. During procedure
Secondary Quality of life due to urinary symptoms If you were to spend the rest of your life with your urinary condition just the way it is now, how would you feel about that?
0 1 2 3 4 5 6
0= delighted
please
mostly satisfied
mixed
mostly unhappy
unhappy
terrible
Before procedure and 7 months after procedure
Secondary Number of subjects with incidental cancer Pathology report of prostate tissue, presence or absence of prostate cancer. 2 weeks after procedure
See also
  Status Clinical Trial Phase
Recruiting NCT05443451 - BETTY: BEnign Prostatic Hyperplasia Transperineal Targeted Microwave therapY N/A
Recruiting NCT04288427 - 5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy N/A
Not yet recruiting NCT05017285 - Ejaculation Preservation After Laser Enucleation Prostate N/A
Completed NCT02778243 - Sexual Steroids: Relationship Between Serum and Prostatic Tissue Level N/A
Completed NCT04212403 - Antibiotic Prophylaxis in Transurethral Prostate Resection (TURP) and Transurethral Bladder Tumour Resection (TURB) N/A
Recruiting NCT05440981 - Implanted Nitinol Device (iTind) System in Chinese Males With Lower Urinary Tract Symptom Secondary to BPH N/A
Recruiting NCT05531240 - Transurethral Prostate Resection (TURP) vs. Prostate Artery Embolization (PAE) N/A
Recruiting NCT03176017 - Ejaculatory Sparing Transurethral Incision Of The Prostate (ES-TUIP) Versus Conventional TUIP N/A
Completed NCT02244294 - FLOMAX® Versus Placebo, in Male Patients With Acute Urinary Retention Related to Benign Prostatic Hyperplasia (BPH) Phase 2
Recruiting NCT03966950 - Use of Melatonin for Preventing POCD in Transurethral Prostate Resection Under Spinal Anesthesia N/A
Recruiting NCT06116851 - Prostate Metabolism, Cancer Risk and Gut Microbiota
Completed NCT04781985 - Prostatic Resection Cavity Stone Post Transurethral Resection of the Prostate (TURP). A Rare Case Scenario N/A
Not yet recruiting NCT01876836 - Clasic Laryngeal Mask Airway(C-LMA) and I-gel Releated Regurgitation and Complications Phase 4
Not yet recruiting NCT05941260 - Standardization of Prostatic Resection by Virtual Computational Reconstruction and Computational Flow Dynamics
Completed NCT04580628 - Thuflep/SOLEP : Initial Experience and Results of Prostate Laser Enucleation With Thulium-fiber Laser (TFL)
Completed NCT04848181 - The Effect of Pre-operative Use of Finasteride Versus Cyproterone Acetate on Blood Loss With Transurethral Resection of Prostate Early Phase 1
Completed NCT04781049 - Transperineal Laser Ablation vs Transurethral Resection for Benign Prostatic Obstruction: A Randomized Clinical Trial N/A
Completed NCT05059431 - The Effect of Human Prostate Tissue on Platelet Activation
Completed NCT05108662 - Inflammatory Markers: HOLEP Versus TURP N/A
Completed NCT04275076 - HoLEP Vs BPEP for Large Prostatic Adenoma Phase 3